期刊
GENE THERAPY
卷 19, 期 1, 页码 49-60出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/gt.2011.71
关键词
AAV; integration-deficient lentiviral vector; corticospinal tract; transduction; spinal cord injury
类别
资金
- Research Councils UK
- British Pharmacological Society
- Friends of Guy's Hospital
- Biotechnology and Biological Sciences Research Council
- EU [222878]
- Genoma Espana
- Medical Research Council [G0600998] Funding Source: researchfish
- MRC [G0600998] Funding Source: UKRI
The corticospinal tract (CST) is extensively used as a model system for assessing potential therapies to enhance neuronal regeneration and functional recovery following spinal cord injury (SCI). However, efficient transduction of the CST is challenging and remains to be optimised. Recombinant adeno-associated viral (AAV) vectors and integration-deficient lentiviral vectors are promising therapeutic delivery systems for gene therapy to the central nervous system (CNS). In the present study the cellular tropism and transduction efficiency of seven AAV vector serotypes (AAV1, 2, 3, 4, 5, 6, 8) and an integration-deficient lentiviral vector were assessed for their ability to transduce corticospinal neurons (CSNs) following intracortical injection. AAV1 was identified as the optimal serotype for transducing cortical and CSNs with green fluorescent protein (GFP) expression detectable in fibres projecting through the dorsal CST (dCST) of the cervical spinal cord. In contrast, AAV3 and AAV4 demonstrated a low efficacy for transducing CNS cells and AAV8 presented a potential tropism for oligodendrocytes. Furthermore, it was shown that neither AAV nor lentiviral vectors generate a significant microglial response. The identification of AAV1 as the optimal serotype for transducing CSNs should facilitate the design of future gene therapy strategies targeting the CST for the treatment of SCI. Gene Therapy (2012) 19, 49-60; doi:10.1038/gt.2011.71; published online 12 May 2011
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据